For: | Bouziana SD, Tziomalos K. Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. World J Gastrointest Pharmacol Ther 2013; 4(1): 4-8 [PMID: 23516172 DOI: 10.4292/wjgpt.v4.i1.4] |
---|---|
URL: | https://www.wjgnet.com/2150-5349/full/v4/i1/4.htm |
Number | Citing Articles |
1 |
Daniel M. Provencher. An update on nonalcoholic fatty liver disease. Journal of the American Academy of Physician Assistants 2014; 27(7): 18 doi: 10.1097/01.JAA.0000450801.19545.93
|
2 |
Yun-Jung Yang, Mi-Hyang Jung, Seok-Hoo Jeong, Yeon-Pyo Hong, Yeong In Kim, Sang Joon An. The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES). International Journal of Environmental Research and Public Health 2020; 17(24): 9568 doi: 10.3390/ijerph17249568
|
3 |
Virender Kumar, Xiaofei Xin, Jingyi Ma, Chalet Tan, Natalia Osna, Ram I. Mahato. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Advanced Drug Delivery Reviews 2021; 176: 113888 doi: 10.1016/j.addr.2021.113888
|
4 |
Shaojun Shi, Monique M. A. Verstegen, Laura Mezzanotte, Jeroen de Jonge, Clemens W. G. M. Löwik, Luc J. W. van der Laan. Necroptotic Cell Death in Liver Transplantation and Underlying Diseases: Mechanisms and Clinical Perspective. Liver Transplantation 2019; 25(7): 1091 doi: 10.1002/lt.25488
|
5 |
Wen-Dee Chiang, Marthandam Asokan Shibu, Kuei-I Lee, Jia-Ping Wu, Fuu-Jen Tsai, Lung-Fa Pan, Chih-Yang Huang, Wan-Teng Lin. Lipolysis-stimulating peptide-VHVV ameliorates high fat diet induced hepatocyte apoptosis and fibrosis. Journal of Functional Foods 2014; 11: 482 doi: 10.1016/j.jff.2014.08.003
|
6 |
Konstantinos Tziomalos. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World Journal of Hepatology 2014; 6(10): 738-744 doi: 10.4254/wjh.v6.i10.738
|
7 |
Mai Miyasato, Yuko Murase-Mishiba, Megumi Bessho, Masahiro Miyawaki, Hisashi Imbe, Chiharu Tsutsumi, Keiji Tanimoto, Akihisa Imagawa, Jungo Terasaki, Toshiaki Hanafusa. The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Clinica Chimica Acta 2014; 433: 184 doi: 10.1016/j.cca.2014.03.018
|
8 |
Shanel Dhani, Yun Zhao, Boris Zhivotovsky. A long way to go: caspase inhibitors in clinical use. Cell Death & Disease 2021; 12(10) doi: 10.1038/s41419-021-04240-3
|